Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novavax NVAX -- Ignore unavailable to you. Want to Upgrade?

To: Glenn Petersen who wrote (55)	8/5/2009 9:11:34 AM
From: Rock_nj	Respond to of 166

Novavax quarterly report and conference call are tomorrow. I think we might get more information on their manufacturing and sales plans tomrrow. That could push NVAX higher.

To: Glenn Petersen who wrote (55)	8/10/2009 1:17:07 PM
From: Rock_nj	Respond to of 166

Cadila Pharma to produce swine flu vaccine (with Novavax) TNN 10 August 2009, 06:38pm IST NEW DELHI: Ahmedabad-based Cadila pharma to become the first firm to manufacture vaccine for H1N1 in India. US-based biotechnology firm Novavax, in which Cadila has equity stake, has developed vaccine for the treatment of H1N1 virus. Two shots of vaccine within 3-week period will immunize person against flu. Cadila says clinical trials on animals have been completed and tests on humans will begin in Ahmedabad shortly. Cadila is approaching government for fast track clearance and hopes to manufacture vaccine by 2009 end. Initialy, it plans capacity of 2 million vaccines per month. timesofindia.indiatimes.com